(UroToday.com) In the on-demand poster session of the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Wassim Abida presented an analysis of the safety and efficacy of tazemetostat in combination with abiraterone and prednisone or enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC).